Alcon gains first FDA prescription drug nod since Novartis split, scoring with drops for dry eye disease
Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first FDA approval for a prescription drug, scoring a nod for dry eye disease treatment Tryptyr.
Six years after being spun out from Novartis and becoming a public company, eye care specialist Alcon has gained its first FDA approval for a prescription drug, scoring a nod for dry eye disease treatment Tryptyr.
